Kobayashi, Yoshihisa http://orcid.org/0000-0003-2057-408X
Chhoeu, Chhayheng
Li, Jiaqi
Price, Kristin S. http://orcid.org/0000-0003-4300-6413
Kiedrowski, Lesli A.
Hutchins, Jamie L.
Hardin, Aaron I. http://orcid.org/0000-0003-1231-0658
Wei, Zihan http://orcid.org/0000-0001-9234-3497
Hong, Fangxin
Bahcall, Magda
Gokhale, Prafulla C. http://orcid.org/0000-0002-1974-5921
Jänne, Pasi A. http://orcid.org/0000-0002-7821-4928
Article History
Received: 24 November 2020
Accepted: 20 January 2022
First Online: 2 March 2022
Competing interests
: P.A.J. reports consulting fees from AstraZeneca, Boehringer-Ingelheim, Pfizer, Roche/Genentech, Takeda Oncology, ACEA Biosciences, Eli Lilly and Company, Araxes Pharma, Ignyta, Mirati Therapeutics, Novartis, Loxo Oncology, Daiichi Sankyo, Sanofi Oncology, Voronoi, SFJ Pharmaceuticals, Silicon Therapeutics, Nuvalent, Esai, Bayer, Biocartis, Allorion Therapeutics, Accutar Biotech and AbbVie; receiving post-marketing royalties from DFCI owned intellectual property on EGFR mutations licensed to Lab Corp; sponsored research agreements with AstraZeneca, Daichi-Sankyo, PUMA, Boehringer Ingelheim, Eli Lilly and Company, Revolution Medicines and Astellas Pharmaceuticals; and stock ownership in Loxo Oncology and Gatekeeper Pharmaceuticals. K.S.P., L.A.K., J.L.H. and A.I.H. are employees and stockholders of Guardant Health. P.A.J. and Y.K. are inventors on a patent on the therapeutic use of mutant specific antisense oligonucleotides.